Literature DB >> 30629300

Incorporating antibiotics into platelet-rich fibrin: A novel antibiotics slow-release biological device.

David Polak1, Navit Clemer-Shamai1, Lior Shapira1.   

Abstract

BACKGROUND: The aim of the present in vitro study was to explore the possibility of using platelet-rich fibrin (PRF) as a local sustained released device for antibiotics.
MATERIALS AND METHODS: Platelet-rich fibrin was prepared with the addition of antibiotics (5 mg/ml metronidazole; 150 mg/ml clindamycin; 1 mU/ml penicillin) or saline prior to centrifugation, while collagen sponges served as control. PRFs anti-bacterial properties were examined in an anti-biogram assay with Staphylococcus aureus or Fusobacterium nucleatum at different time intervals after PRF preparation.
RESULTS: The addition of antibiotic solutions at volumes of 2 or 1 ml led to significant changes in PRF's physical properties, while the addition of 0.5 ml solution did not. PRF with saline showed minor anti-bacterial activity, while all PRFs with antibiotics showed significant anti-bacterial activity (p < 0.05). No differences were observed between raw (clot) and pressed (membrane) forms of PRF. Collagen sponges with and without antibiotics showed similar results to PRF. PRF and collagen sponges with antibiotics preserved their anti-bacterial properties 4 days after preparation.
CONCLUSIONS: Platelet-rich fibrin incorporated with antibiotics showed long-term anti-bacterial effect against F. nucleatum and S. aureus. This modified PRF preparation may be used to reduce the risk of post-operative infection in addition to the beneficial healing properties of PRF.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Year:  2019        PMID: 30629300     DOI: 10.1111/jcpe.13063

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  7 in total

1.  Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam.

Authors:  Anton Straub; Andreas Vollmer; Thiên-Trí Lâm; Roman C Brands; Maximilian Stapf; Oliver Scherf-Clavel; Max Bittrich; Andreas Fuchs; Alexander C Kübler; Stefan Hartmann
Journal:  Clin Oral Investig       Date:  2022-08-09       Impact factor: 3.606

2.  Titanium platelet-rich fibrin (T-PRF) as high-capacity doxycycline delivery system.

Authors:  Esra Ercan; Selin S Suner; Coskun Silan; Selehattin Yilmaz; Duygu Siddikoglu; Nurettin Sahiner; Mustafa Tunali
Journal:  Clin Oral Investig       Date:  2022-05-03       Impact factor: 3.606

3.  Comparison of the Postoperative Effects of Local Antibiotic versus Systemic Antibiotic with the Use of Platelet-Rich Fibrin on Impacted Mandibular Third Molar Surgery: A Randomized Split-Mouth Study.

Authors:  Ceren Melahat Donmezer; Kani Bilginaylar
Journal:  Biomed Res Int       Date:  2021-12-02       Impact factor: 3.411

Review 4.  From Blood to Regenerative Tissue: How Autologous Platelet-Rich Fibrin Can Be Combined with Other Materials to Ensure Controlled Drug and Growth Factor Release.

Authors:  Karina Egle; Ilze Salma; Arita Dubnika
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

5.  Impact of local and systemic antimicrobials on leukocyte- and platelet rich fibrin: an in vitro study.

Authors:  S A M Siawasch; C Andrade; A B Castro; W Teughels; A Temmerman; M Quirynen
Journal:  Sci Rep       Date:  2022-02-17       Impact factor: 4.379

6.  Methodological variations affect the release of VEGF in vitro and fibrinolysis' time from platelet concentrates.

Authors:  Leonel Alves de Oliveira; Tatiana Karla Borges; Renata Oliveira Soares; Marcelo Buzzi; Selma Aparecida Souza Kückelhaus
Journal:  PLoS One       Date:  2020-10-07       Impact factor: 3.240

7.  Clinical and radiographic effects of ascorbic acid-augmented platelet-rich fibrin versus platelet-rich fibrin alone in intra-osseous defects of stage-III periodontitis patients: a randomized controlled clinical trial.

Authors:  Mohamed Talaat Elbehwashy; Manal Mohamed Hosny; Ahmed Elfana; Alaa Nawar; Karim Fawzy El-Sayed
Journal:  Clin Oral Investig       Date:  2021-04-12       Impact factor: 3.573

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.